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Abstract
Subclinical Hypothyroidism, SCH, has been detected with increasing frequency in recent years and has brought about major 
controversies regarding management and treatment [Meier et al ., 2001] . The condition is characterized as having a high concen-
tration of thyroid stimulating hormone, yet normal thyroid hormone levels and is often asymptomatic. Scientific articles retrieved 
from various databases helped determine some of the long term risk factors associated with SCH, including progression to overt 
hypothyroidism, fatty liver disease, cardiovascular disease, neuropsychiatric complications and reproductive malfunctions . Studies 
determining the clinical and metabolic effects of L-thyroxine hormone replacement therapy on symptoms and potential risks of 
SCH on various patient populations were investigated and compared to controls that were not treated or were given a placebo 
drug . After considering both the arguments promoting treatment and others opposing it, conclusions were drawn regarding the 
promotion or discouragement of hormonal treatment for patients in different age brackets and stages of life .  In general, the 
greatest benefits of treatment are observed in patients with thyroid-stimulating hormone levels ranging over 10mIU/L, younger 
patients with slightly elevated thyroid-stimulating hormones who are at risk for cardiovascular disease and for pregnant women 
with gestational SCH . On the contrary, L-thyroxine treatment therapy is not as crucial for the elderly population or patients with 
slightly elevated thyroid-stimulating hormone values when there are no apparent symptoms of hypothyroidism being experienced .
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Introduction
Describing a condition as ‘subclinical’ implies that it is asymptom-
atic, thereby suggesting that a less aggressive treatment plan is 
needed and possibly rendering the condition unworthy of treat-
ment altogether. However, there is controversy regarding wheth-
er the condition is indeed ‘subclinical’ and if it is necessary or 
beneficial to treat. Hypothyroidism is an endocrinological disor-
der in which there is inadequate production of thyroid hormones, 
triiodothyronine (T3) and thyroxine (T4) by the thyroid gland. 
These hormones strongly influence energy metabolism, digestion 
and body heat production. Additionally, they play a key role in car-
diac contraction rate, memory, psychological health and sleep. In 
the case where the gland itself fails to secrete sufficient hormone 
concentrations, the disease is considered primary. However, if the 
root of the problem is traced back to insufficient stimulation of 
a structurally healthy gland due to decreased thyroid-stimulating 
hormone (TSH) released from the adenohypophysis, then the 
condition is regarded as secondary or central. Diminished secre-
tion of thyrotropin-releasing hormone (TRH) from the hypothal-
amus would cause the condition to be considered tertiary hypo-
thyroidism [Hadley & Levine, 2007; Wiersinga, 2010].  Subclinical 
hypothyroidism (SCH)  ranks as a grade of primary hypothyroid-
ism and is characterized biochemically as an elevated serum TSH 
concentration, with a normal serum-free T4 level, as well as T3 
level [Meier et al.,2001]. When a patient’s thyroid function is nor-
mal and hormone secretion is balanced according to homeostasis, 
he/she is considered euthyroid.  Euthyroid adults should exhibit 
TSH levels within a range of 0.2-7.6 mIU/L, a T3 concentration 
of 4.3-12.5 mcg/dL and a free T4 concentration of 0.7-1.7 ng/dL 
[Robertson, Shilkofsky 2005]. Some experts have suggested that 
the TSH upper limit should be only 2.5 or 3 mU/L, while others 
argue that the serum TSH distribution gradually shifts towards 
higher values with age and must be adjusted accordingly. Others 
have proven through their studies that the accepted reference 
range for serum TSH should be altered as patients age and that 
maintaining a 4.5 mIU/L upper limit for TSH concentration results 
in the prevalence of SCH to be significantly overestimated in the 
elderly population. Nonetheless, while there is controversy over 
the appropriate upper limit of normal serum TSH, most laborato-
ries agree that it is 4 to 5 mIU/L [Surks et al.,2007]. Biochemical 
testing and laboratory test results alone are required in order 
to diagnose SCH since patients often present with vague symp-
toms elevated TSH levels. Much research has been done regard-
ing whether to treat SCH in populations of various age brackets 
and stages. A general consensus has been reached based on the 
existing and potential risk factors involved and the success rates 
of levothyroxine thyroid hormone replacement.
Methods
Relevant information was accumulated via original research 
literature obtained from databases such as Google Scholar, 
Proquest , Pubmed and Touro College’s Online Library . Medical 
journals, JCEM and JAMA, served as a source of information 
as well. Books, including a medical book and science textbook, 
were used to provide background information. All content was 
critically analyzed and compared to assure validity.
Epidemiology
Based on the results of population-based studies, the preva-
lence of SCH in adults ranges from 4 to 15 percent [Turnbridge 
et.al., 1977] and affects approximately 10 million people in the 
Unites States [Huber et al., 2002]. In one of the best longitudinal 
studies conducted, Turnbridge et al. (1977) found that 7.5% of 
women and 2.8% of men of all ages in Whickham, England  have 
TSH levels exceeding 6 mlU/L. Twelve such studies done with-
in different cultures, similar to theirs, were reviewed, and they 
concluded that primary thyroid-gland malfunction occurs in 
approximately 5% of any population. Of the 16,533 participants 
in the Unites States Third National Health and Examination 
Survey (NHANES III), 4.3% had SCH [Hollowell et.al., 2002]. 
Of the 25,862 participants included in the Colorado Thyroid 
Disease Prevalence Study, an elevated TSH level was found in 
9.5% of the population [Canaris et. al., 2000]. Furthermore, the 
frequency of SCH is found to be higher in females than males, 
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rises with age and is less in blacks than in whites [Kanaya et 
al., 2002]. It is important to note that since thyroid hormones 
contain iodine, the inhabitants’ thyroid functioning is highly de-
pendent on the iodine reserve of their specific region. When 
analyzing population-based studies, it’s crucial to consider how 
the degree of iodine repletion or depletion in that geographical 
environment affects its populations intake and in turn, thyroi-
dal health [Laurberg et al., 1998]. For example, in Africa, lack 
of dietary iodine is the chief determinant of thyroid pathology, 
instigating a spectrum of iodine deficiency disorders, including 
hypothyroidism [Okosieme, 2006].
Clinical Findings
While the clinical manifestations of SCH vary, patients some-
times report mild signs and symptoms similar to those experi-
enced due to overt hypothyroidism. However, these symptoms 
are characterized as neither sensitive nor specific [Meier et 
al., 2001]. Based on the Colorado Thyroid Disease Prevalence 
Study involving 2,336 participants with SCH, symptoms report-
ed by patients with SCH  included dry skin (28%), poor mem-
ory (24%), slow thinking (22%), muscle weakness (22%), fatigue 
(18%), muscle cramps (17%), cold intolerance (15%), puffy eyes 
(12%), constipations (8%) and a hoarser voice(7%) [Canaris 
et al., 2000]. Conflicting data is seen from a community-based 
cross-sectional study where 1,423 participants, ranging from 
ages 18-75 years old, had TSH screenings and their symptoms 
were evaluated. The data collected indicated that subclinical thy-
roid disease is not associated with lower well-being or impaired 
health-related quality of life. Therefore, attempts to clinically 
identify SCH based on reported symptoms are unsuccessful 
[Bell et al., 2007]. However, significant evidence highlights nu-
merous long-term consequences of SCH, though they do not 
appear obvious from patients’ reports.
Progression to Overt Hypothyroidism
A significant number of patients with SCH eventually develop 
overt hypothyroidism. In a study done by Huber et al., after a 
mean observation period of 9.2 years, 23 out oof 82patients 
(28%) who entered the study with subclinical hypothyroidism 
developed overt hypothyroidism, as defined by low T4 concen-
tration and elevated TSH (>20 mU/L). The risk of progression to 
overt hypothyroidism was seen to correlate to the initial serum 
TSH level of the patient; the higher the concentration, the great-
er the risk. Of the 82 women with TSH concentration values 
ranging from 4-6 mIU/L, the frequency of progression to overt 
hypothyroidism was 0% after 9.2 years. When only the patients 
with a serum TSH concentration above 6 mIU/L were evaluat-
ed (n = 61), after 10 years, the cumulative incidence of overt 
hypothyroidism was 55.3% [Huber et al., 2002]. Overt hypo-
thyroidism is particularly common in older patients whose TSH 
levels exceed 10 mIU/L or those who have circulating thyroid 
antibodies [Ayala et al., 2000]. Obviously, overt hypothyroidism 
poses a greater threat to one’s overall health related quality of 
life as it presents with classical symptoms of fatigue, depression, 
weight gain, cold intolerance, bradycardia, constipation, dry skin, 
facial edema and loss of hair [Carle et al., 2014]. More severe 
dysfunction of the thyroid gland also stimulates a negative feed-
back mechanism in which more and more TSH is secreted, ulti-
mately causing the gland to swell, referred to as goiter.
Fatty-liver Disease
Since thyroid hormones play a fundamental role in lipid me-
tabolism, mild hypothyroidism may cause hypercholesterolemia 
and play an essential role in the pathogenesis of non-alcoholic 
fatty liver disease (NAFLD). Non-alcoholic fatty liver disease is 
defined as “extrahepatic accumulation of fat in the absence of 
excess alcohol consumption” [Liu et al., 2017]. A cross-sectional 
study reported the prevalence of fatty-liver disease and abnor-
mal liver enzyme levels to increase progressively with rising TSH 
levels compared to patients with euthyroidism, suggesting asso-
ciations between the spectrum of SCH and liver malfunction. In 
one study population, the incidence of fatty-liver disease and ab-
normal liver enzyme level was 29.9% and 20.1%, respectively, for 
patients with SCH [Chung et al., 2012].  SCH patients experi-
ence higher amounts of liver aspartate aminotransferase  (AST) 
and alanine aminotransferase (ALT), an enzyme released into 
the bloodstream when the liver is damaged [Liu et al., 2017].
Cardiovascular Disease
Thyroid hormones are known to affect the heart and vascu-
lature.  As a result, the impact of SCH on the cardiovascular 
system has become an important subject of research [Liu et 
al., 2010]. While it is undisputed that overt hypothyroidism is 
linked to increased risk for cardiovascular diseases (CVD), con-
flicting data raises controversy whether SCH is also associated 
with heart disease.  Heterogeneity among individual studies can 
be explained by the different TSH cutoffs used, varying cardio-
vascular disease definitions or differences in participants’ age, 
gender, or severity of SCH (as measured by TSH level) [Rodondi 
et al., 2010]. Clinical hypothyroidism has been known to cause 
an increase in blood pressure. Since thyroid hormone directly 
acts on arterial smooth muscle cells of blood vessels, causing 
vasodilation, when hypothyroidism occurs, a lower hormone 
level increases the vascular resistance and in turn the level of 
blood pressure. In a cross-sectional survey the incidence of high 
blood pressure, hypertension, in the SCH group was significant-
ly higher than the control, the euthyroid group. The conclusions 
drawn from this study coincide with previous data collected by 
Luboschitzky et al. in 2002 [cited in Liu et al., 2010].
Furthermore, since SCH has been linked with abnormal lipid 
metabolism, it is consequently related to increased risk for 
coronary heart disease. An increased serum total cholesterol 
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and low density lipoprotein cholesterol (LDL-C) was detected 
as a feature of SCH in some of the literature, while contrast-
ing research found cholesterol levels to be in normal range. 
Nonetheless, several studies suggested a connection between 
SCH and development of atherosclerosis, and more recently 
published research established SCH as a risk factor for myo-
cardial infarction [Meier et al., 2001; Anderson et al. 2015].  A 
meta-analysis from 7 studies, including 2,020 patients with SCH, 
confirmed a substantial trend of increased risk of coronary 
heart disease by highlighting events like nonfatal myocardial 
infarction, angina and necessary coronary revascularizations 
common to patients with elevated serum TSH concentrations, 
especially of those that were 10 mIU/L or greater. Results from 
a meta-analysis of patient-level data from 11 prospective cohort 
studies showed greater risk for coronary heart disease mortal-
ity for patients suffering from SCH with serum TSH concentra-
tions above 10mIU/L. Rodoni et al. reported increased systemic 
vascular resistance, arterial stiffness, altered endothelial func-
tion, increased atherosclerosis and altered coagulability to be 
associated with SCH and the acceleration of development of 
coronary heart disorder. On the contrary, minimal TSH eleva-
tion (4.5-6.9 mIU/L) was not linked to cardiovascular disease or 
mortality [Rodoni et al., 2010]. 
Neuropsychiatric Symptoms
While there is evidence that SCH is linked to neuropsychiatric 
complications, there has been conflicting research as well.  One 
study assessed the history of major depression in subjects with 
SCH compared to euthyroid subjects. The frequency of depres-
sion was substantially higher in those who met the criteria for 
SCH (56%) than in those who did not (20%), suggesting that 
SCH may lower the threshold for the occurrence of depression 
[Haggerty et al., 1993]. Similar results were found in a later study 
where signs of neuropsychiatric dysfunction like somatization, 
cognitive impairment disturbances, psychomotor retardation 
and sleep disorders were seen in 63.5% of a population with 
mild thyroid failure [Demartini et al., 2010]. However, another 
study revealed opposite research as patients with SCH scored 
equally as well as the euthyroid control group on 14 cognitive 
function tests [Jorder et al., 2006].
Reproductive Malfunctions
Alteration of the thyroid’s physiology under the impact of pla-
cental human chorionic gonadotropin (hCG) during the first 
trimester, results in adjustments to TSH levels.  During the first 
trimester, a white woman maintains an upper limit TSH concen-
tration of 2.5 mIU/L and 3.0 mlU/L during her second and third 
trimester periods [Stagnaro-Green et al., 2011].  SCH during 
gestation poses fewer risks than overt hypothyroidism would, 
but still puts women at increased risk for preterm delivery at or 
before 34 weeks of gestation, placental abruption (3 times more 
likely to occur in women with SCH) and/or pregnancy loss 
compared to euthyroid women. Severe preeclampsia, defined as 
gestational hypertension is noted as a risk factor for pregnant 
women with SCH [Casey et al. 2005;Novakovic et al., 2018]. 
A meta-analysis of 15 cohort studies involving 1,896 pregnant 
women with SCH arrived at conclusions similar to Novakovik 
et al. and showed that SCH during gestation causes significant 
impairment to the intelligence and neurological development of 
the offspring [Liu et al., 2018].
It’s possible to acquire SCH as a result of pregnancy; an esti-
mated 15% of pregnancies in the U.S are affected by gestational 
SCH [Blatt et.al., 2012].  Over the gestational period, increased 
metabolic needs result in increased production of thyroid hor-
mones by approximately 50% compared to euthyroid, non-preg-
nant women. Consequently, necessary daily iodine intake levels 
rise by 50%.  More renal blood flow and glomerular filtration 
results in an increase in iodide clearance from blood plasma. 
Thus, more iodine is necessary in the diet of a pregnant woman. 
The stress imposed on the thyroid gland during gestation re-
sults in SCH for many women with compromised dietary io-
dine levels.  Clinical studies have proven that iodine deficiency 
during gestation causes impaired development of the brain and 
impedes mental function development of the fetus [Farebrother 
et al., 2015 ]. Measuring the IQ of children whose mothers had 
not been treated for SCH during pregnancy revealed mean IQ 
scores of 7 points lower than controls [Haddow et al., 1999]. 
Casey et al. (2005) proposed that preterm parturition results in 
prematurity which contributes to neurodevelopment delay and 
reduces intelligence quotient.
Effects of Levothyroxine Hormone Replacement
In general, the research showing correlation between T4 re-
placement and improvement of hypothyroid symptoms is con-
flicting and is probably due to differences in the populations 
studied, various TSH cut-off concentrations and age range. 
Levothyroxine, which is a synthetic form of T4, is usually ad-
ministered to patients suffering from overt hypothyroidism. 
Nevertheless, there is much controversy whether patients ex-
hibiting mild thyroid failure with similar symptoms should be 
prescribed levothyroxine as well [Meier et al., 2001]. Some, but 
not all, research conducted show how treatment facilitates im-
provement of hypothyroid symptoms experienced by patients 
with SCH. Subjects with mild thyroid failure who were treat-
ed with L-thyroxine showed significantly greater improvement 
in overall hypothyroid symptoms than did subjects who were 
given placebo [Cooper et al., 1984]. Nonetheless, in all the clini-
cal trials reviewed, with ongoing dosage monitoring, L-thyroxine 
succeeded in lowering previously elevated TSH concentrations 
to healthy levels. 
By decreasing TSH concentration to euthyroid levels, 
L-Thyroxine prevents the progression to overt hypothyroidism 
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[Ayala et al., 2000]. Following T4 treatment, ultrasound verified 
80% thyroid volume reduction in patients with goiter [Romaldini 
et al., 1996].  In one study, L- thyroxine and a placebo drug were 
randomly administered to 63 female patients over a span of 48 
weeks in order to achieve euthyroid TSH levels.  In the thyrox-
ine treated group, the mean serum TSH concentration was 12.8 
± 1.4 mIU/liter before and 3.1 ± 0.3 mIU/liter after treatment, 
whereas TSH levels remained unchanged in the control group. 
When lipid concentrations were measured after thyroxine 
treatment, it was observed that the total cholesterol and low 
density lipoprotein cholesterol decreased substantially, especial-
ly in those with TSH concentrations of 12 mIU/L and above. 
From the observed improvement, it is approximated that treat-
ment reduces the risk of cardiovascular disease and mortality by 
9-31%. In contrast, no change in any variable of thyroid function 
occurred in the placebo group (Meier et al., 2001).  Substantial 
improvement of cardiac function in treated patients was reflect-
ed by a sensitive measure of myocardial contractility [Cooper 
et al., 1984]. In a study done in Copenhagen, Denmark, the par-
ticipating cohort included patients over 18 years old with the 
mean age being 55.2 years. The total of 12,212 subjects were 
subdivided into 2 groups, one with TSH levels of 5-10 mIU/L and 
another with TSH levels above 10 mIU/L; some were treated 
from both groups. In this large cohort study no association be-
tween treatment and risk of myocardial infarction or mortality 
was revealed, besides in younger patients where it may seem 
that treatment had marginal protective advantage. However, 
limitations of the study such as no access to patients’ blood 
pressure or serum lipid levels and a relatively short follow-up 
period of 5 years cause it to have less credence since patients 
could have suffered from cardiac complication later on in time 
[Anderesen et al., 2015].
A study involving 415 patients with SCH (defined as TSH ≥ 
4.2 mlU/L) administered levothyroxine to measure its effect on 
non-alcoholic fatty liver disease and abnormal liver enzyme lev-
els. After treatment with LT4, the incidence of fatty liver disease 
in patients with more pronounced SCH (TSH concentration 
≥10 mlU/L) reduced from 48.5% to 24.2%, while in patients 
with milder SCH (TSH concentration 4.2-10 mlU/L), frequen-
cy of fatty liver disease and alanine aminotransferase was not 
significantly altered by LT4 supplementation. However, mild 
SCH patients with elevation of total cholesterol who received 
LT4 treatment showed decreases in the incidence of fatty liver 
disease and serum alanine aminotransferase levels. Those with 
higher TSH values experienced a decrease of 5.61 IU/L in serum 
aspartate aminotransferase and a small decrease in serum al-
anine aminotransferase. Patients with milder SCH showed a 
reduction in serum alanine aminotransferase from 19.09 IU/L 
to 17.95 IU/L, yet serum aspartate aminotransferase remained 
stable throughout the study in the untreated, mild SCH control 
group.  Observing how these parameters became less prevalent 
in patients who received treatment, but remained comparably 
stable in patients who weren’t treated, provides concrete evi-
dence of the success LT4 therapy has with prevention of non-al-
coholic fatty liver disease [Liu et al., 2017].
In another randomized double-blind, placebo-controlled trial, 
TSH values decreased by 8.6 mIU/L. Patients treated with with 
LT4 showed improved psychometric memory score involving 
their thinking, memory and attention versus untreated control 
patients [Jaeschke et al., 1996].  Unfortunately, in another study, 
LT4 treatment was not enough to generate complete remission of 
depressive symptoms, suggesting psychiatric evaluation in patients 
affected in this way by SCH is needed [Demartini et al., 2010].
Regarding SCH during gestation, miscarriage was significantly 
less frequent among treated women compared to untreated 
women in a national U.S. cohort of 5,405 pregnant women. 
However, the treated group also had increased odds for 
preterm delivery, gestational diabetes and preeclampsia [Maraka 
et al., 2017]. Conflicting data claims LT4 decreased the rate of 
preterm delivery considerably in pregnant women who re-
ceived treatment compared to their control who did not (SCH 
defined as TSH ≥4 MIU/L; 5.3% incidence for treated women 
versus 29.4% in control group) [Nazarpour et al., 2017]. Further 
complicating the matter, another study revealed no difference 
in the prevalence of preterm delivery, gestational hypertension, 
miscarriage rates or adverse fetal outcomes between women 
who received LT4 treatment and those who got the placebo 
[Casey et al., 2017].  During pregnancy, beginning treatment for 
compensated maternal iodine status to ensure proper brain 
development in the fetus is extremely time-sensitive; until the 
end of the second trimester, iodine treatment protects the 
neurological system from consequences of iodine deficiency. 
Since head circumference reflects brain mass, the head circum-
ference of an underdeveloped child will be significantly dimin-
ished.  Microcephaly, where head circumference is more than 3 
standard deviations below the norm, was diagnosed in 27% of 
children of untreated mothers as opposed to 11% frequency in 
their treated control [Cao et al., 1994]. Yet, opposing data says 
that no significant discrepancies are noted when comparing IQ 
scores and neurodevelopment of 5 year old children of mothers 
who received LT4 to those who took the placebo drug [Casey 
et al., 2017]. Additional research trials are needed to determine 
whether LT4 therapy during gestation prevents adverse out-
comes, possibly induces some issues or simply doesn’t have any 
effect at all.
In opposition to treating SCH, various studies, such as the 
meta-analysis of 12 clinical trials (9 of them with TSH concen-
tration cut-offs of less than 10,12 and 15 mU/L), show no chang-
es in hypothyroid symptoms or quality of life in the treated 
group versus the control, the group who received the placebo 
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drug [Villar et al., 2007]. While SCH and cognitive dysfunction 
have been linked, T4 treatment in a population over 65 years 
of age proved it to be ineffective for aiding cognitive function 
[Parle et al., 2010]. Similarly, a double-blind, randomized, place-
bo-controlled, parallel-group trial involving 737 adults (65 years 
of age+, TSH levels ranging from 4.60-19.99 mIU/L with a mean 
TSH of 6.40±2.01 mIU/L) concluded that there are no apparent 
benefits to  L-thyroxine treatment in the quality of life in older 
adults. There was no benefit observed in regard to hypothyroid 
symptoms, executive cognitive function as measured by the 
letter-digit coding test or degree of lethargy experienced by 
the group whom received treatment. However, after 12 months, 
the mean TSH level was 5.48±2.48 mIU/L in the placebo group, 
as compared with 3.63±2.11 mIU/L in the levothyroxine group; 
clearly, in terms of reaching healthy TSH levels, the treatment 
was successful [Stott et al., 2017]. 
While research supports that untreated SCH during preg-
nancy is linked to many adverse obstetric outcomes, many 
claim that insufficient evidence exists supporting the benefit 
of LT4 therapy on clinical improvement for women with SCH. 
Implementing guidelines to treat all pregnant women with SCH 
would lead to prescription of LT4 for up to 600,000 pregnant 
women in the U.S every year which would obviously have enor-
mous impact on the cost of healthcare [Maraka et al., 2017]
Strengthening the argument that SCH should not be treated, 
there is potential danger for a patient to overdose on levothy-
roxine, causing TSH values to decrease abnormally. Statistical 
analysis claims that the incidence of this is as frequent as 10-
33% as treated SCH patients exhibit unusually low TSH levels. 
Overtreatment would completely reverse the original condition 
inducing symptoms of excess thyroid hormone. Many times, 
this is due to polypharmacy and drug interaction; research 
done reiterates the importance in monitoring TSH therapy in 
the older population, because of risk of over-replacement. In 
their trial with 339 thyroid hormone users, 41% had a low TSH, 
16% had a high TSH, and 43% were in the euthyroid range after 
treatment [Parle et al., 1993;Somwaru et al., 2009]. Additionally, 
those against treatment resent the lifelong commitment to daily 
medication in asymptomatic patients, and the cost for both the 
hormone and for consistent monitoring of its efficacy. 
Conclusion
Based on the results of T4 replacement successfully reducing 
hypothyroid symptoms and potential risks associated with SCH 
in certain populations, it is recommended that LT4 replacement 
be given to those patients who present with abnormal thyroid 
function tests. The most obvious benefit appears to be limited 
to patients with baseline TSH levels of ≥10 mIU/L as they are 
most likely to experience progression to overt hypothyroidism, 
atherosclerosis, myocardial infarction and non-alcoholic fatty 
liver disease. The research regarding pregnant women with SCH 
poses no doubt to experts and healthcare providers in their 
unanimous decision to err on the side of caution and prescribe 
levothyroxine substitution for both the mother’s and fetus’s ad-
vantage. Adverse obstetric effects and risk factors far outweigh 
any arguments against treatment. However, treatment of patients 
with minimally elevated TSH values (between 4.5 and 10 mlU/L; 
differing depending on individual study TSH cut-off) demon-
strated minimal change in health related quality of life and only 
burdened patients with responsibilities to monitor treatment 
and cover its cost, suggesting that these patients not be treated. 
However, based on the increased protection against cardiovas-
cular disease and mortality in treated younger patients (<65 
years) with TSH ranging from 7 to 9.9 mIU/L, some recommend 
treatment. But in the elderly population where LT4 treatment 
exacerbates the issue of polypharmacy and may instigate harm-
ful drug-interactions, coupled with the fact that there is a lack of 
treatment trials showing benefit of treatment in this population, 
only those who present with symptoms suggestive of hypothy-
roidism should be treated. Of course, long-term monitoring and 
annual clinical evaluation of TSH concentration should be im-
plemented to help ensure optimal dosage. Whether reference 
ranges should be adjusted for age, implementing a higher cutoff 
for starting treatment in older patients, awaits further research. 
Future research clarifying the reference ranges for thyroid func-
tion tests, specifically the upper limit for TSH, will help resolve 
conflicting data and enable researchers to easily compare data 
from different clinical trials in order to determine whether or 
not the condition requires levothyroxine treatment.
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